CYP2B6 and major depressive disorder: Overall, the foregoing study was unable to provide evidence that the Val66Met or CYP2B6 genotypes significantly predict antidepressant, anti-suicidal, anxiolytic, or average dissociative response in patients with treatment-resistant major depression receiving repeated intravenous ketamine.